D-Glu-Fniii14

General Information


DRACP ID  DRACP01161

Peptide Name   D-Glu-Fniii14

Sequence  TeATITGLEPGTEYTITVIAL

Sequence Length  21

UniProt ID  Not available

PubChem CID  Not available

Origin  Not available

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
U-937 Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia Leukemia As show in fig3 WST-1 assay 24 h Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  e=D-Glutamic acid

Chiral  Mix



Physicochemical Information


Formula  C93H152N20O31

Absent amino acids  CDFHKMNQRSW

Common amino acids  T

Mass  240327

Pl  3.61

Basic residues  0

Acidic residues  2

Hydrophobic residues  8

Net charge  -2

Boman Index  496

Hydrophobicity  66.67

Aliphatic Index  116.19

Half Life 
  /

Extinction Coefficient cystines  1490

Absorbance 280nm  74.5

Polar residues  9

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID EP2716297B1

Patent Title  D-Glu-Fniii14 Polypeptide for Use in Treating Cancer

Other Iinformation  Granted Patent; Family: 8s / 8ex; Family Jurisdictions: JP, WO, US, EP; Legal Status: Active; Application No: 12758028; Filed: Mar 9, 2012; Published: Sep 27, 2017; Earliest Priority: Mar 11, 2011; Granted: Sep 27, 2017

Other Published ID  EP2716297A4  EP2716297B1  JP5924593B2  JPWO2012124641A1  US2014005120A1  US9327013B2  WO2012124641A1 




DRACP is developed by Dr.Zheng's team.